Susan Collins

If this leaked draft opinion is the final decision and this reporting is accurate, it would be completely inconsistent with what Justice Gorsuch and Justice Kavanaugh said in their hearings in our meetings in my office.

We don't want to see a gap.

We know that the agreement that was reached is going to expire this summer; do we anticipate there are going to be further disruptions?

I can assure you, from talking to my colleagues, and state commissioners, that this guidance has created a lot of angst, and concern, and it is in conflict with our intent.

Will you rescind or revise that memo?

What can we do to ensure that we follow the practice that we have always followed?

Unfortunately, this is not the case in Maine.

I was very surprised to see that your budget is again proposing to zero out this program.

It is important that the record be corrected on this issue.

I just, you know, when I look at your previous efforts to eliminate the University of Maine's Agricultural Lab altogether during the Obama administration, and restrict the use of potatoes, despite the Institute of Medicine's study, that…

You stated that 'you were under the impression you are providing indemnity for livestock in addition to fluid milk.'

Mr. Secretary, we received a response to that letter at 1:24 a.m. this morning.

I told you that in 2016 a dairy farmer in Arundel, Maine, had discovered that the milk that was being produced by his cattle contains some of the highest levels ever reported from a PFAS contaminant.

I have heard serious concerns that FDA is responding to some meeting requests with a 'written response only.'

We have had a great success, I believe, and we have got another agency of the Federal Government that just absolutely cut our legs out from under us.

I fear it will discourage research and have an impact on the pipeline of drugs.

What concerns me in this case is not FDA's approach. I think you stayed within your lanes.

I hope that we will be able to fill it.

Congress charged the FDA, not CMS, to be the agency responsible for evaluating the safety and efficacy of biomedical products.

In light of the decision by CMS, do you question the FDA's decisionmaking regarding Aduhelm's accelerated approval?

Could you please explain to the subcommittee how the Department can justify arguing in court that the pandemic has subsided enough to warrant the termination of Title 42?

In Maine, we set a horrific new record, 636 people died from drug overdoses.

Drug development is hamstrung by the fact that we simply do not have well characterized the endpoints for most rare diseases.

More than half of the 400 million people in the world who are affected by rare diseases are children, and about one-third of those children will sadly die before the age of five.

Dr. Esham accelerated approval is a critical regulatory pathway that provides timely review of treatments for patients with serious and life threatening conditions for which there is an unmet need.